Newsletter

Welcome to

PROVIDING PATIENTS THERAPEUTIC RELIEF FROM SERIOUS DISEASES WITH HIGH UNMET MEDICAL NEED

Relief is a biopharmaceutical company with its lead compound RLF-100™ (aviptadil) in advanced clinical development to treat severe COVID-19 patients. We focus on critical illnesses with high unmet medical need ranging from niche to widespread. Through rapid development of late-stage clinical assets, we aim to bring therapeutic options to patients as quickly as possible.

Latest News

  • COVID-19 PROJECT

    COVID-19 PROJECT

    Realizing the urgent unmet medical need created by the 2019 SARS-CoV-2 pandemic, Relief mounted a swift plan of action to respond to one of the largest healthcare disasters of our time by rapidly advancing our proprietary asset RLF-100™ into clinical development and towards approval in COVID-19 induced lung injury. RLF-100™ is outpacing traditional clinical development timelines to meet the necessary safety and efficacy requirements.